Levonorgestrel, Pharmacokinetics, Efficacy and Safety 61serious adverse events are rare among women taking any of these ECP
formulations [167].
Levonorgestrel is a highly effective and safe synthetic progestogen used in
different forms, for contraception and treatment of certain gynecological
conditions.
REFERENCES
[1] De Lignierès B, Dennerstein L, Backstrom T. Influence of route of
administration on progesterone metabolism. Maturitas. 1995;21:251–
257.
[2] Graham D, Clarke CL. Physiological action of progesterone in target
tissues. Endocrinol. Rev. 1997; 52: 502-519.
[3] Richter TA, Robinson JE, Evans NP. Progesterone blocks the estradiol-
stimulated luteinizing hormone surge by disrupting activation in
response to a stimulatory estradiol signal in the ewe. Biol Reprod. 2002;
67:119-25.
[4] Schindler AE, Campagnoli C, Druckmann D, Huber J, Pasqualini R,
Schweppe KW, et al. Progestins: present and future. J. Steroid Biochem.
Molec. Biol. 1996; 59: 357–363.
[5] Rozenbaum H Les Progestatifs ESKA, Paris; 2002.
[6] Sitruk-Ware R, Michel’le DR, editors. Progestins and antiprogestins in
clinical practice. New York: Marcel Decker; 2000.
[7] Rozenbaum H. Comment choisir un progestatif? Reproduction Humaine
et Hormones 2000;XIII:3–16.
[8] Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR,
Schweppe KW, Thijssen JH. Classification and pharmacology of
progestins. Maturitas. 2003; 46(Suppl 1):S7–S16.
[9] Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and
structurally related contraceptive steroids. Contraception. 1990; 42:67–
96.
[10] Golbs S, Nikolov R, Zimmermann T. Pharmacology of Nortestosterone
Derivatives. Menopause Review. 2001; VI: 31–7.
[11] Stanczyk FZ. Structure-function relationships, potency, and
pharmacokinetics of progestogens. In: Lobo RA, editor. Treatment of the
postmenopausal woman: Basic and Clinical aspects. New York: Raven
Press; 1994. pp. 69–89.